ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Sept. Is AMA’s Month of Women In Medicine

September 10, 1993

“NCI activities at Frederick are not well integrated…. It would be wise to reorganize and consolidate.”

July 21, 1995

New Protocol Could Improve Survival Of Rare Brain Tumor

October 30, 2009

B-27 Finds Improved CR For Taxotere Prior To Surgery

November 28, 2003

Tobacco Council Grants Total 3,348

July 15, 1988

ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials

December 31, 2010